Trial Profile
LEVOsimendan before Heart-Lung-Machine in coronary artery bypass graft operations.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2014
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms LEVOHLM
- 29 Apr 2014 Primary endpoint 'Sequential-Organ-Failure-Assessment' has not been met.
- 29 Apr 2014 Results published in the Journal of International Medical Research.
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2007-004674-49).